The National Institute of Allergy and Infectious Diseases (NIAID) recently published its 2026-2030 Strategic Plan, the institute’s first major strategic update in about a decade. The plan marks a dramatic shift away from NIAID’s longstanding focus on three core areas: HIV/AIDS, biodefense and pandemic preparedness, and all other infectious and immunologic diseases.
Instead, NIAID will narrow its focus to conducting and supporting research on infectious and immune-mediated diseases, reporting that biodefense and pandemic preparedness are no longer within the institute’s purview.
New Research Goals
The plan is organized around three research goals: foundational research, diagnostics and prevention, and treatments and cures. These goals are supported by three cross cutting themes: person-centered research, research technology, and health across the lifespan, with additional objectives related to institute operations and organizational capacity. Emphasizing their person-centric approach and focus on human immunology, the NIAID strategic plan aligns itself with HHS- and NIH-wide priorities to improve health outcomes and tackle the issues and diseases currently facing Americans.
Immunology Still at the Center
The plan repeatedly emphasizes the importance of immunology research to improving human health: “NIAID’s core priority is advancing foundational knowledge of human immunology. This knowledge is needed to enhance protective immune responses that prevent disease, while reducing harmful responses that lead to disease. Understanding the continuum of immune responses, including how intrinsic factors influence this balance, is essential to achieving these goals.” Encouragingly, it also includes strong language about the continued strong need for animal research models: “the use of animals in several research area remains necessary to advance medical and scientific knowledge.”
Notable Absences
The absence of pandemic preparedness and biodefense is notable in light of news of a research agreement between NIH and the Department of Defense (DoD). The deal came under scrutiny from Congress and the scientific community for being secretive and potentially a way to divert money from NIH to alleviate DoD financial pressures. NIH Director Jay Bhattacharya said that the agreement is on a project-by-project basis and allows NIH and DoW to collaborate on shared missions.
In May of 2024, AAI submitted comments in response to the Request for Information seeking feedback on the draft NIAID strategic plan. Among other things, AAI emphasized foundational and discovery-based research, support for biomedical workforce development, and the responsible use of animals in research.
